Close Icon We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.

Pharma Intelligence is part of the Business Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Products:

Pharma Consulting

Close Icon

Hot topics

Thought leadership

Research and development strategy

Close Icon

Events

Conferences 2018

Awards

Upcoming Webinars

Webinar recordings

Close Icon

Global Search Configuration

Search Site Products & Services
Close Icon

Search by Keyword

Focus
Needs

pharmaceutical companies pharma intelligence

The partner of choice for pharmaceutical companies

Bring game-changing drugs to market more efficiently. We’ll help you understand the competition to hone in on your strategies to improve healthcare and patient outcomes.

Get drugs to market faster

adevelopment partner pharma intelligence

The right drugs developed at the right time transform pharmaceutical and biotechnology companies and improve patients’ lives. But the process is long and complex, taking place in an ever-changing, intensely competitive arena.

How we help
As the trusted pharma research partner of the top 50 global pharmaceutical companies, we provide reliable, timely intelligence and insights to help you every step of the way during drug development.

We can help you:

Optimize your clinical trials
Stay ahead of the competition by fully understanding future patient needs
Tailor your portfolio and commercial strategies to market needs
Identify opportunities and overcome potential threats across your pipeline
Stay current and be prepared for market shifts
Access historical success rates, and development and regulatory durations from a large number of perspectives

Our unique strengths

Identify market opportunities

Understand where future drug and development opportunities lie with access to the industry’s leading forecasts and behind-the-headlines analysis.

Capitalize on treatment trends

Keep on top of global trends and access source information on the impact of developing technologies.

Approach reimbursement proactively

Our reimbursement analysis can assist your business planning – both at the early stages of product development and long after product launch.

View competitor activity

Get unique competitor insight with our detailed reviews of your competitors’ clinical trials and our ability to track all drugs in development.

View more
View Less

Relevant products

Thought leadership

Key benefits:

Build brand credibility
Generate Leads
Effective reporting

Awareness

Key benefits:

Direct access to your target Pharma audience
Multi or single channel campaigns
Effective reporting

Lead generation

Key benefits:

Direct access to your target Pharma audience
Multi or single channel campaigns
Measurable results

View all content

Scrip

New Chugai CEO Lays Course As He Takes Reins

By Ian Haydock 25 May 2018

Chugai's new CEO Tatsuro Kosaka took up his position in March and is charged with taking the major Japanese company through the next stage of development as key products reach the global market and others begin to face biosimilar competition. In this first part of a two-part exclusive interview, he outlines the firm's vision, approach to R&D and how the strategic alliance with Roche is playing out.

Topic Business strategies Research

View article
Scrip

Remember When Provenge's Price Was Bold? Every New Cancer Drug In 2017 Cost $100,000 Or More

By Jessica Merrill 25 May 2018

The price of new oncology brands doubled in the US from 2013 to 2017, bringing the median annual price to more than $160,000 last year, up from $79,000 in 2013, according to a new IQVIA report. Spending on cancer drugs in the US has doubled since 2012, reaching nearly $50bn in 2017.

Topic Cancer

View article
Scrip

Pfizer's Three-Pronged Oncology Strategy Includes Expanding Ibrance, Xtandi, Developing Blockbuster Combos

By Brenda Sandburg 23 May 2018

Xtandi use in early prostate cancer, lorlatinib as second-line treatment for non-small cell lung cancer and dacomitinib for first-line NSCLC have upcoming user fee dates.

Topic Cancer

View article
Scrip

Missing In Action: China’s Best Shot In Ebola Vaccine Race

By Brian Yang 23 May 2018

As the Congo grapples with the latest outbreak of Ebola, China has approved its first domestically developed vaccine in record time, hailing it a national innovation champion. But as the World Health Organization starts vaccinations in Africa, can China make the cut and compete with global players including Merck & Co?

Topic Vaccines

View article
Scrip

Pharma Backs UK Parliament Report As 'No Deal Brexit' Fears Grow

18 May 2018

The pharmaceutical sector has given its backing to a report from MPs which warns that a no-deal Brexit will have a hugely damaging effect on the industry in the country, turning it into "a second-tier state for new and innovative medicines."

Topic Brexit Business strategies

View article
Scrip

Immuno Oncology: What To Watch At ASCO 2018

By Emily Hayes 18 May 2018

Cancer immunotherapy is once again set to dominate the upcoming American Society of Clinical Oncology annual meeting, with a continuing showdown for PD-1 inhibitors in lung cancer, a CAR-T battle, and disappointments for new IO classes.

Topic Cancer

View article
Trialtrove

2017 Completed Trials

By Christine Blazynski, PhD 16 May 2018

As Informa Pharma Intelligence has done for the past three years, this analysis examines the landscape of industry-sponsored clinical trials completed during 2017, of which there were a total of 3,534 Phase I through Phase III/IV. The nearly 700 trials terminated in 2017 were not included in this analysis.

Topic Clinical trials

View white paper
Scrip

First Of Its Kind: Beam Seeks To Erase-And-Replace Single Letters In DNA's Alphabet

By Mandy Jackson 16 May 2018

Beam Therapeutics combines new insights from gene-editing pioneers to allow for single-letter editing of DNA and RNA. The company has raised $87m to develop DNA base-editing for therapies that in some diseases could be more efficient than CRISPR gene editing.

View article
Scrip

NewLink CEO Reflects On Golden Age And Rapid Fall Of IDO

By Emily Hayes 16 May 2018

There is now a move back to the principle of doing randomized Phase II studies before jumping into Phase III, says CEO Chuck Link, as Roche's Genentech exits broad IDO/TDO deal.

Topic Cancer

View article
Scrip

FDA Refuse-To-File Letter For Alkermes Depression Drug Suggests A Lengthy Commercial Delay

By Jessica Merrill 15 May 2018

CEO Richard Pops called FDA's letter for ALKS 5461 "surprising and troubling." Alkermes had been ramping up to launch the depression drug later this year, though some investors had remained skeptical.

Topic FDA Drug approval

View article
Scrip

From Pharma Insider To Payer: Witty To Lead United's Optum

By Jessica Merrill 15 May 2018

Former GSK CEO Witty stood out among big pharma chief execs for his pessimistic outlook on US drug pricing, which shaped his diversification strategy at GSK. His experience as a pharma insider makes him an interesting choice to lead United's PBM and health services arm.

Topic Drug review

View article
Scrip

GSK Gains Clarity For Pharma Focus Through Novartis Consumer JV Buy

By Mandy Jackson 15 May 2018

GSK removed some uncertainty about how much it could invest in pharma R&D and business development by purchasing Novartis' share of the firms' Consumer Healthcare Joint Venture. Now it can more accurately allocate capital as it prepares for battle in HIV and braces for Advair generics.

Topic Business strategies

View article
Scrip

IPO Update: Will Declining Returns Slow Fast Pace Of Biopharma Offerings?

By Mandy Jackson 15 May 2018

Offerings by Homology, Unum and Genprex at the end of March brought the first quarter's biopharma IPO total to 14 in the US, putting 2018 on track to beat the 2017 total of 42. But with the average return for this year's IPOs dropping, the pace of offerings could slow.

Topic Company analysis

View article
Scrip

Opdivos EU Colorectal Cancer is a Setback but More Than Offset By Potential Gains

By Ian Schofield 15 May 2018

Bristol-Myers Squibb has withdrawn its EU application to extend Opdivo’s use to metastatic colorectal cancer (mCRC), following a similar move for liver cancer last year. But the mCRC withdrawal is likely to have limited commercial impact and the company is more interested in pursuing the product’s use in combination treatment for this indication.

Topic Cancer

View article
Scrip

Workforce Roundtable Part 1: Recruiting Biopharma Leaders As The Talent Pool Shrinks

By Mandy Jackson 15 May 2018

As Baby Boomers age out of the workforce, they'll be replaced in biopharma C-suites and boardrooms by a younger, more female and racially diverse group. A panel of current and former life science CEOs, venture investors and recruiters discuss the challenges and opportunities ahead.

Topic Business strategies

View article

Latest headlines

Scrip

25 May 2018

BioMarin Gets Second PKU Approval, Anticipates Slow Ramp-Up For Palynziq

Link
Scrip

25 May 2018

After Phase III Amyloidosis Failure Prothena Slashes Workforce In Restructuring

Link
Scrip

25 May 2018

PACIFIC Pays Off Again For AZ With Imfinzi Lung Cancer OS Success

Link
Scrip

25 May 2018

Astellas Culls Positions Ahead Of Big Expiry

Link
Scrip

24 May 2018

Sanofi In Pole Position In Oral Type 1 Diabetes With Zynquista Filings

Link
Scrip

24 May 2018

New Chugai CEO Lays Course As He Takes Reins

Link
Scrip

24 May 2018

Former Gilead CSO Bischofberger Lands At Kronos As C-Suite Moves To Start-Ups Continue

Link
Scrip

24 May 2018

Deal Watch: Allergan, Celgene, AstraZeneca Among Biopharmas Advancing Existing Partnerships

Link
Scrip

24 May 2018

More Evidence Needed For Chiesi’s Ultra Orphan Lamzede, Says NICE

Link
Scrip

24 May 2018

Novo Nordisk Boosts Specialty R&D With Kidney Disease Deal

Link
Scrip

23 May 2018

Cipla Sounds The Bugle On US Respiratory Ambition

Link
Scrip

23 May 2018

Merck's Stellar Keytruda Squamous Lung Cancer Data Refute Naysayers

Link
Scrip

23 May 2018

Cara’s Partnership With Vifor Fresenius Provides Validation For Pruritis Drug Korsuva

Link
Scrip

23 May 2018

Strides’ Founder Resumes Charge After Dismal Q4 Earnings

Link
Scrip

23 May 2018

Severe Asthma Market Snapshot: A Competitive Therapy Area That Will Test Payers' Influence

Link

Next steps

Request a live demo

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Request a free demo

How can we help you?

Our team is always happy to hear from you. Please call us at:

US Toll-Free : +1 888 670 8900
US Toll : +1 908 547 2200
UK & Europe : +44 (20) 337 73737
Australia : +61 2 8705 6907
Japan : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

The partner of choice for pharmaceutical companies

Get drugs to market faster

Our unique strengths

Identify market opportunities

Capitalize on treatment trends

Approach reimbursement proactively

View competitor activity

Relevant products

Below are the Product List

Thought leadership

Awareness

Lead generation

Pharma Intelligence latest insights

Latest headlines

Next steps

This is Contactus Section

Request a live demo

How can we help you?

Report store